BriaCell Therapeutics (NASDAQ:BCTX – Get Free Report) had its goal worth lower by equities researchers at HC Wainwright from $18.00 to $15.00 in a report launched on Thursday, Benzinga stories. The agency at present has a “purchase” score on the inventory. HC Wainwright additionally issued estimates for BriaCell Therapeutics’ FY2029 earnings at ($0.05) EPS.
BriaCell Therapeutics Inventory Up 7.7 %
BriaCell Therapeutics inventory opened at $0.65 on Thursday. The corporate’s 50-day shifting common worth is $0.70 and its 200-day shifting common worth is $1.55. BriaCell Therapeutics has a twelve month low of $0.46 and a twelve month excessive of $6.36. The corporate has a market cap of $11.87 million, a PE ratio of -0.52 and a beta of 1.31.
Institutional Buying and selling of BriaCell Therapeutics
A hedge fund just lately raised its stake in BriaCell Therapeutics inventory. Onyx Bridge Wealth Group LLC lifted its holdings in BriaCell Therapeutics Corp. (NASDAQ:BCTX – Free Report) by 66.7% in the course of the first quarter, in accordance with the corporate in its most up-to-date 13F submitting with the Securities & Alternate Fee. The fund owned 50,000 shares of the corporate’s inventory after shopping for a further 20,000 shares in the course of the interval. Onyx Bridge Wealth Group LLC owned about 0.31% of BriaCell Therapeutics price $143,000 on the finish of the newest reporting interval. 15.42% of the inventory is at present owned by institutional traders and hedge funds.
About BriaCell Therapeutics
BriaCell Therapeutics Corp. operates as a Section 3 biotechnology firm remodeling most cancers care with its novel mobile immunotherapies. It’s conducting a pivotal Section 3 medical trial in superior breast most cancers with its Bria-IMT together with an immune examine level inhibitor. It’s also creating personalised off-the-shelf therapies for breast most cancers, prostate most cancers, and different cancers.
Learn Extra
Obtain Information & Rankings for BriaCell Therapeutics Day by day – Enter your e mail tackle under to obtain a concise day by day abstract of the most recent information and analysts’ rankings for BriaCell Therapeutics and associated firms with MarketBeat.com’s FREE day by day e mail e-newsletter.